Cardiology

Results show no differences in one-year outcomes

Device intended as alternative to oral anticoagulants in atrial fibrillation

Takeda Canada is introducing a new angiotensin II blocker (ARB) for the treatment of hypertension.

Forest Laboratories will soon launch a new once-daily beta-blocker for the treatment of mild to moderate essential hypertension.

Problem seems to occur when drug is used for the treatment of acute exacerbations of COPD or community acquired pneumonia.

Cinacalcet no better than placebo at reducing cardiovascular risk

Treatment helps maintain vascular access patency in hemodialysis

Ultrasound finds aortic calcification in newborns